Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Phase 2

Novartis Pharmaceuticals